Uliledlimab is under clinical development by I-Mab and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase II drugs for Epithelial Ovarian Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Uliledlimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Uliledlimab overview

Uliledlimab is under development for the treatment of solid tumors including metastatic lung cancer, head and neck cancer squamous cell carcinomas including oral cavity, oropharynx, hypopharynx, or larynx, fallopian tube cancer, primary peritoneal cancer, ovarian clear cell carcinoma, non-small cell lung cancer, triple-negative breast cancer (TNBC), ovarian cancer and adenocarcinoma of the gastroesophageal junction. The drug candidate is developed based on hybridoma and phage display technologies. It acts by targeting CD73. It is administered through intravenous route.

I-Mab overview

I-Mab is a biopharmaceutical company. It develops transformational medicines for therapeutic areas of immuno-oncology and autoimmune diseases. Its pipeline product portfolio comprises TJ202, a CD38 antibody for treating multiple myeloma; TJ101, a recombinant human growth hormone (rhGH) used in pediatric patients with growth hormone deficiency; TJ301, an IL-6 inhibitor for ulcerative colitis; enoblituzumab, a B7-H3 antibody against tumors; and TJ107, an oncology care agent to treat cancer treatment-related lymphopenia. I-Mab utilizes various molecular engineering platforms to develop drug molecules with defined biological properties. It operates in China, Hong Kong and the US. I-Mab is headquartered in Rockville, Maryland, the US.

For a complete picture of Uliledlimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.